Pavan Kumar Puvvula

Pavan Kumar Puvvula has extensive experience in the field of research and development. Pavan Kumar currently holds the position of Principal Scientist at Kodikaz Therapeutic Solutions, Inc, starting in November 2021.

Before joining Kodikaz Therapeutic Solutions, Inc, Puvvula worked at Geisinger Medical Center from 2013 to 2022. During their tenure as a Staff Scientist, they focused on the discovery and development of SAFA-derived anti-cancer cell-penetrating peptides and the development of breast cancer-specific cell-penetrating peptides. As a Research Scientist at Geisinger, they conducted research projects related to TBX3 interactions with ciliary proteins, the development of CAPER alpha conditional knockout mice, the development of tbx3 point mutant mice using CRISPR-CAS technology, and the molecular mechanism of CAPER alpha-MLL1 complex in breast cancer initiation and tumorigenicity.

Prior to their work at Geisinger, Puvvula served as an Assistant Professor in the Pediatrics department at the University of Utah School of Medicine from 2010 to 2013. During this time, they focused on understanding the molecular mechanism of TBX3-mediated splicing regulation in embryonic development and studying the functional significance of TBX3 and CAPER alpha interaction in cellular senescence.

Pavan Kumar Puvvula started their education history in 2001 when they pursued a Doctor of Philosophy (PhD) in Biotechnology at the National Center for Cell Science, University of Pune, India. Pavan Kumar completed their PhD program in 2007. Following that, Puvvula worked as a Researcher at the Pasteur Institute from 2006 to 2007. Later on, they served as a Postdoctoral Research Associate at The Rockefeller University from 2007 to 2010.